HomeCompareMACK vs ABBV

MACK vs ABBV: Dividend Comparison 2026

MACK yields 99.70% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MACK wins by $3.75M in total portfolio value
10 years
MACK
MACK
● Live price
99.70%
Share price
$15.15
Annual div
$15.10
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.85M
Annual income
$1,294,525.08
Full MACK calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MACK vs ABBV

📍 MACK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMACKABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MACK + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MACK pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MACK
Annual income on $10K today (after 15% tax)
$8,474.74/yr
After 10yr DRIP, annual income (after tax)
$1,100,346.32/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MACK beats the other by $1,079,290.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MACK + ABBV for your $10,000?

MACK: 50%ABBV: 50%
100% ABBV50/50100% MACK
Portfolio after 10yr
$1.98M
Annual income
$659,648.42/yr
Blended yield
33.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MACK
Analyst Ratings
6
Buy
4
Hold
1
Sell
Consensus: Buy
Altman Z
5.0
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MACK buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMACKABBV
Forward yield99.70%3.06%
Annual dividend / share$15.10$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$3.85M$102.3K
Annual income after 10y$1,294,525.08$24,771.77
Total dividends collected$3.44M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: MACK vs ABBV ($10,000, DRIP)

YearMACK PortfolioMACK Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$20,670$9,970.29$11,550$430.00+$9.1KMACK
2$41,378$19,260.63$13,472$627.96+$27.9KMACK
3$80,308$36,033.62$15,906$926.08+$64.4KMACK
4$151,290$65,360.39$19,071$1,382.55+$132.2KMACK
5$276,955$115,075.35$23,302$2,095.81+$253.7KMACK
6$493,221$196,878.70$29,150$3,237.93+$464.1KMACK
7$855,424$327,677.50$37,536$5,121.41+$817.9KMACK
8$1,446,436$531,132.26$50,079$8,338.38+$1.40MMACK
9$2,387,024$839,337.57$69,753$14,065.80+$2.32MMACK
10$3,848,641$1,294,525.08$102,337$24,771.77+$3.75MMACK

MACK vs ABBV: Complete Analysis 2026

MACKStock

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Full MACK Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MACK vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MACK vs SCHDMACK vs JEPIMACK vs OMACK vs KOMACK vs MAINMACK vs JNJMACK vs MRKMACK vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.